Reviva Pharmaceuticals Holdings Inc is a clinical development pharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases.
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
Reviva Pharmaceuticals Holdings Inc is a clinical development pharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Reviva Pharmaceuticals Holdings Inc is a clinical development pharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Lantern Pharma leverages AI, machine learning and genomics to rescue and develop targeted cancer therapies. The company's RADR platform contains over 4.6 billion data points covering drug and tumor interactions. Lantern is developing a portfolio of targeted cancer drugs including LP-100, LP-184, LP-300 and novel ADC programs. The company aims to identify patient populations most likely to respond to therapies to streamline drug development and maximize success.
Lantern Pharma leverages AI, machine learning and genomic data to transform oncology drug development. Their RADR platform identifies patient subgroups likely to respond to drug candidates to increase success rates. They are developing multiple oncology drug programs including LP-100 for prostate cancer through a precision trial. LP-300 targets never-smoker NSCLC adenocarcinoma based on prior data and biomarker studies. Lantern aims to reduce costs and time through AI-enabled approaches.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
NE3107 is a small molecule in Phase 3 clinical trials for Alzheimer's disease and Parkinson's disease. It works by inhibiting neuroinflammation and insulin resistance, two key drivers of cognitive decline. A Phase 3 trial for Alzheimer's is underway testing NE3107's ability to slow cognitive decline compared to placebo. Preclinical studies show NE3107 reduces inflammation, enhances insulin sensitivity, and has neuroprotective effects, supporting its potential in neurodegenerative diseases. A Phase 2 trial will assess NE3107's activity and safety when combined with L-dopa for Parkinson's disease.
Reviva Pharmaceuticals Holdings Inc is a clinical development pharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Reviva Pharmaceuticals Holdings Inc is a clinical development pharmaceutical company. It is developing a portfolio of internally discovered therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic and inflammatory diseases.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
Lantern Pharma leverages AI, machine learning and genomics to rescue and develop targeted cancer therapies. The company's RADR platform contains over 4.6 billion data points covering drug and tumor interactions. Lantern is developing a portfolio of targeted cancer drugs including LP-100, LP-184, LP-300 and novel ADC programs. The company aims to identify patient populations most likely to respond to therapies to streamline drug development and maximize success.
Lantern Pharma leverages AI, machine learning and genomic data to transform oncology drug development. Their RADR platform identifies patient subgroups likely to respond to drug candidates to increase success rates. They are developing multiple oncology drug programs including LP-100 for prostate cancer through a precision trial. LP-300 targets never-smoker NSCLC adenocarcinoma based on prior data and biomarker studies. Lantern aims to reduce costs and time through AI-enabled approaches.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to
developing and commercializing novel therapeutics to tackle unmet medical needs.
Aptorum's current drug pipeline includes indications in orphan diseases, infectious
diseases, and metabolic diseases. In 2021, the company plans to bring two candidates to
clinical trials. Aptorum’s Smart-ACT™ platform is designed to bring an average of three
drug candidates for orphan diseases to clinical trials every 12-18 months. The company is
now preparing to launch a dietary supplement for women undergoing menopause and
experiencing related symptoms, including osteoporosis. Targeting a global woman’s health
supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to
generate near-term revenue with significant long-term growth potential.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met all endpoints for its phase 2 clinical trial and the Company is now preparing for a phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody approach is a proven Mechanism of Action and has shown efficacy as a combination therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. It also recently began enrolling for a phase 2 clinical trial for the treatment of Cystic Fibrosis patients with acute pneumonia, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with its novel inhalation antibody technology for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Visit BIVIinfo.com to learn more.
Tiziana Life Sciences presented an overview of their transformational immunotherapy platform enabling alternative routes of administration. Their proprietary technologies allow for oral, nasal, and inhalation delivery of antibodies, which currently require IV administration. They highlighted clinical progress including trials of their lead asset foralumab administered intranasally for progressive MS and COVID-19. Results demonstrated safety and positive clinical responses. Tiziana is also developing other pipeline assets and expanding their management team and scientific advisory board.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Tiziana Life Sciences provides an update on their clinical pipeline, including completing a study of nasally administered Foralumab in COVID-19 patients that showed positive responses, initiating several phase 2 trials with Foralumab and Milciclib, and executing an agreement with Precision Biosciences to use Foralumab to improve CAR-T cell therapy outcomes for cancer treatment. The company is developing oral and intranasal formulations of antibodies to enable local tissue delivery and reduce costs and side effects compared to IV administration. Milciclib is advancing in clinical trials as a potential treatment for cancers like hepatocellular carcinoma and KRAS-mutated
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
This document provides an overview of G Medical Innovations and its mobile medical devices and monitoring services. It summarizes that G Medical develops FDA-approved mobile devices that collect diagnostic health data and enable remote patient monitoring to improve outcomes and reduce healthcare costs. The company has a growing portfolio of products and services and sees significant market potential to expand direct-to-consumer sales and the number of customers that include insurance providers, hospitals, clinics, and physicians. G Medical aims to capitalize on the large market for remote patient monitoring and digital health solutions to help manage the rising complexity and costs of healthcare.
Genetic Technologies is an Australian company focused on developing and commercializing genetic risk assessment tests. The presentation provides an overview of the company's business, including its portfolio of current and upcoming genetic tests, markets and channels to market, and capabilities. Key points include:
- Genetic Technologies aims to offer the most comprehensive suite of genetic risk assessment tests on the market, covering up to 70% of disease risks.
- The company is prioritizing market entry strategies in key regions like Australia, the US, and Asia.
- Tests are marketed through consumer-initiated and medical business-to-business channels.
- An innovative pipeline of new tests for diseases like cancer, heart disease, and diabetes is being
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Opexa Therapeutics August 2015 OPXA Corporate PresentationOpexaTherapeutics
Opexa Therapeutics presented information on their precision immunotherapy platform and key programs. Their lead candidate, Tcelna, is in Phase 2b clinical trials for secondary progressive multiple sclerosis and has shown signs of stabilizing disease progression. Tcelna works by reducing myelin reactive T-cells that damage the myelin sheath. Opexa has an option agreement with Merck Serono for the development and commercialization of Tcelna in multiple sclerosis. Additionally, Opexa is developing OPX-212 for neuromyelitis optica, an orphan indication with no approved therapies.
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries.
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
Virios Therapeutics is a clinical-stage biotechnology company focused on advancing novel, dual mechanism antiviral therapies to treat conditions associated with virally triggered or maintained immune responses, such as Fibromyalgia (“FM”). Immune responses related to the activation of tissue resident Herpes Simplex Virus-1 (“HSV-1”) have been postulated as a potential root cause triggering and/or sustaining chronic illnesses such as FM, irritable bowel disease (“IBS”), and chronic fatigue syndrome, all of which can be characterized by waxing and waning symptom flare-ups with no obvious etiology. Virios’ lead development candidate (“IMC-1”) is a novel, proprietary, fixed dose combination of famciclovir and celecoxib designed to synergistically suppress HSV-1 replication, with the end goal of reducing virally promoted disease symptoms.
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of drug candidates intended to transform existing treatment and prevention paradigms. Its lead Phase 3 antifungal candidate, rezafungin, will report Phase 3 data at the end of 2021. The potential peak sales opportunity for rezafungin in the US is ~$750M. In addition, the Company is developing Drug-Fc Conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform.
One in 8 U.S. women will develop invasive breast cancer over her lifetime, with approximately 266,000 new breast cancer patients and 3.1 million breast cancer survivors in 2018. Following breast cancer surgery in the adjuvant setting, a HER2/neu 3+ patient typically receives Herceptin® in the first year, with the hope that their breast cancer will not recur, and with the odds of recurrence slowly decreasing over the first 5 years after surgery. Herceptin® has been shown to reduce recurrence rates from 25% to 12% in the adjuvant setting. In the neoadjuvant setting, a patient receives treatment before surgery and based on the results of a biopsy at surgery, will receive the same or more potent treatment after surgery. Kadcyla® has been shown to reduce recurrence rates from 22% to 11% in the neoadjuvant setting. Accordingly, we believe that GP2 may be used to address the 50% of recurring patients who do not respond to either Herceptin® or Kadcyla®.
Aptorum Group Limited (NASDAQ: APM) is a pharmaceutical company dedicated to
developing and commercializing novel therapeutics to tackle unmet medical needs.
Aptorum's current drug pipeline includes indications in orphan diseases, infectious
diseases, and metabolic diseases. In 2021, the company plans to bring two candidates to
clinical trials. Aptorum’s Smart-ACT™ platform is designed to bring an average of three
drug candidates for orphan diseases to clinical trials every 12-18 months. The company is
now preparing to launch a dietary supplement for women undergoing menopause and
experiencing related symptoms, including osteoporosis. Targeting a global woman’s health
supplement market that is expected to reach $17 billion in 2025, Aptorum is expected to
generate near-term revenue with significant long-term growth potential.
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology.
Aridis Pharmaceuticals is a late-stage clinical development company, leading the creation of transformative, first-in-class anti-infectives for life-threatening viral and bacterial respiratory infections. The company’s lead drug candidate for acute pneumonia met all endpoints for its phase 2 clinical trial and the Company is now preparing for a phase 3 study. Its pipeline of novel mechanism antibacterial and antivirals, sprung from its proprietary technology platforms, are designed to combat the growing public health threat of viral pandemics and antimicrobial resistant (AMR) bacteria. Its anti-toxin monoclonal antibody approach is a proven Mechanism of Action and has shown efficacy as a combination therapy in reducing acute pneumonia patients time in ICU as compared to the current standard of care, which is antibiotics. In addition to its phase 3 program, ARDS also has a phase 2 asset for the treatment of Bacteria HAP/VAP LPS 011. It also recently began enrolling for a phase 2 clinical trial for the treatment of Cystic Fibrosis patients with acute pneumonia, a program funded by the Cystic Fibrosis Foundation for $7.5 million. Importantly, ARDS is also preparing to launch a Phase 1/2 clinical trial in the second half of 2021 with its novel inhalation antibody technology for emerging COVID-19 mutated variants. The expansion of COVID virus strain coverage, combined with the product's self-administered, at-home treatment modality, further differentiates the company's AR-712 COVID treatment offering.
BioVie Inc. (OTCQB: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Visit BIVIinfo.com to learn more.
Tiziana Life Sciences presented an overview of their transformational immunotherapy platform enabling alternative routes of administration. Their proprietary technologies allow for oral, nasal, and inhalation delivery of antibodies, which currently require IV administration. They highlighted clinical progress including trials of their lead asset foralumab administered intranasally for progressive MS and COVID-19. Results demonstrated safety and positive clinical responses. Tiziana is also developing other pipeline assets and expanding their management team and scientific advisory board.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for liver disease. The Company’s drug candidate, BIV201 (continuous infusion terlipressin), has an Orphan Drug designation for the treatment of refractory ascites, FDA Fast Track status, and US patent pending. BIV201 also has an Orphan Drug designation for the treatment of hepatorenal syndrome (HRS). The active agent in BIV201, terlipressin, is approved for use in about 40 countries for the treatment of related complications of advanced liver cirrhosis but is not available in the US or Japan. The FDA has never approved terlipressin. BioVie is targeting this landmark achievement.
Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical and dental applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, virtually painless, and less expensive. Milestone’s proprietary DPS® Dynamic Pressure Sensing technology® platform advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for epidural space identification in regional anesthesia procedures.
Lantern Pharma is a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic date to streamline the drug development process and to identify patients who will benefit from their targeted oncology therapies. Their portfolio of therapies consists of compounds that others have tried, but failed, to develop into an approved commercialized drug. Additionally, they develop new compounds with the assistance of their A.I. platform (RADR) and biomarker driven approach. The Company is currently developing four therapeutic programs.
Tiziana Life Sciences provides an update on their clinical pipeline, including completing a study of nasally administered Foralumab in COVID-19 patients that showed positive responses, initiating several phase 2 trials with Foralumab and Milciclib, and executing an agreement with Precision Biosciences to use Foralumab to improve CAR-T cell therapy outcomes for cancer treatment. The company is developing oral and intranasal formulations of antibodies to enable local tissue delivery and reduce costs and side effects compared to IV administration. Milciclib is advancing in clinical trials as a potential treatment for cancers like hepatocellular carcinoma and KRAS-mutated
SciSparc is a specialty pharmaceutical company developing unique cannabinoid technologies for treatment of central nervous system disorders. The proprietary compounds capitalize on the biochemistry of receptors that specialize in modulating the central nervous system (CNS) to create therapeutics that mitigate the adverse symptoms associated with CNS disorders.
This document discusses Ruthigen, Inc., a drug development company focused on developing RUT58-60, a hypochlorous acid-based drug candidate for invasive use. RUT58-60 aims to improve patient outcomes for invasive procedures by reducing post-surgical infections in a more effective way than current standard of care antibiotics. Published studies on Microcyn, another hypochlorous acid-based product, show promise in reducing infection rates for diabetic foot ulcers and coronary artery bypass graft surgery wounds. If successful, RUT58-60 could help hospitals reduce costs by shortening patient stays and lowering readmission rates for post-surgical infections.
This document provides an overview of G Medical Innovations and its mobile medical devices and monitoring services. It summarizes that G Medical develops FDA-approved mobile devices that collect diagnostic health data and enable remote patient monitoring to improve outcomes and reduce healthcare costs. The company has a growing portfolio of products and services and sees significant market potential to expand direct-to-consumer sales and the number of customers that include insurance providers, hospitals, clinics, and physicians. G Medical aims to capitalize on the large market for remote patient monitoring and digital health solutions to help manage the rising complexity and costs of healthcare.
Genetic Technologies is an Australian company focused on developing and commercializing genetic risk assessment tests. The presentation provides an overview of the company's business, including its portfolio of current and upcoming genetic tests, markets and channels to market, and capabilities. Key points include:
- Genetic Technologies aims to offer the most comprehensive suite of genetic risk assessment tests on the market, covering up to 70% of disease risks.
- The company is prioritizing market entry strategies in key regions like Australia, the US, and Asia.
- Tests are marketed through consumer-initiated and medical business-to-business channels.
- An innovative pipeline of new tests for diseases like cancer, heart disease, and diabetes is being
BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Opexa Therapeutics August 2015 OPXA Corporate PresentationOpexaTherapeutics
Opexa Therapeutics presented information on their precision immunotherapy platform and key programs. Their lead candidate, Tcelna, is in Phase 2b clinical trials for secondary progressive multiple sclerosis and has shown signs of stabilizing disease progression. Tcelna works by reducing myelin reactive T-cells that damage the myelin sheath. Opexa has an option agreement with Merck Serono for the development and commercialization of Tcelna in multiple sclerosis. Additionally, Opexa is developing OPX-212 for neuromyelitis optica, an orphan indication with no approved therapies.
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for mid-2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries.
Reviva is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.
RespireRx Corporate Slide Deck and Non Confidential Shortened VersionRespireRX
RespireRX Pharmaceuticals Inc. is a publicly-traded company listed on the OTCQB under the ticker symbol RSPI. This is not investment advice. Please view the disclaimer found on this website. http://www.respirerx.com
Reata Pharmaceuticals: Creating New Opportunities for PatientsJon Le Culpepper
Bardoxolone methyl consistently increased eGFR in clinical trials involving over 2,800 patients with CKD. In a Phase 2 trial in 30 patients with Alport syndrome, bardoxolone treatment resulted in significant time-dependent increases in eGFR from baseline, with a mean increase of 13.4 mL/min/1.73 m2 by week 12. Nearly all patients experienced increases in eGFR, and over 70% improved their CKD stage by week 12 with no worsening. eGFR increases occurred across subgroups defined by baseline eGFR level, proteinuria level, gender, and age, with no serious safety issues observed.
- The document presents information on Praluent (alirocumab), the first PCSK9 inhibitor therapy approved in the US for treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease who require additional lowering of LDL cholesterol.
- Praluent demonstrated robust and durable LDL-C reduction of over 52 weeks in clinical trials in patients on maximally tolerated statin therapy, with 57-83% of patients achieving sufficient LDL-C reduction with the 75 mg starting dose.
- The Committee for Medicinal Products for Human Use adopted a positive opinion for Praluent in Europe, and approval is expected in late September 2015. The OD
Medicines For Respiratory Diseases
Apneas: Types, Their Measurement, Epidemiology, and Economics
Dronabinol: Breakthrough Treatment for Obstructive Sleep
Apnea
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit, the same word means both breath and life."
Abbot George Burke
Progenity (PROG) Investor Presentation - Nov 30, 2021ssuser6da871
This corporate presentation discusses the company's therapeutics pipeline and programs. The company is developing oral delivery of biotherapeutics using an Oral Biotherapeutics Delivery System to enable needle-free delivery of large molecules. It is also developing GI-targeted therapeutics using a Drug Delivery System to deliver drugs directly to the gastrointestinal tract for improved efficacy and safety. Several product candidates are discussed, as well as potential catalysts and market opportunities for the different programs.
Press Release: RespireRx Pharmaceuticals Inc. Announces Publication of Ampaki...RespireRX
Ampakines are a class of molecules that enhance the actions of glutamate, the major excitatory neurotransmitter in the brain, at its AMPA receptors. Prior to this article, it was believed that the induction of neurotrophic factors was exclusively produced by high impact ampakines, which also produced undesirable side effects such as seizures. In the current study, the Company demonstrated increased levels of brain BDNF and NGF at doses of representative low impact ampakines that are active
in behavioral measures of cognition. Low impact ampakines do not display the side effects associated with high impact ampakines. The results demonstrate that low impact ampakines safely induce differential increases in neurotrophins across several brain regions, providing mechanistic and translational evidence for their activity not only in memory and cognition but also in a variety of central nervous system disorders, including ADHD and spinal cord injury. The paper can be downloaded at https://authors.elsevier.com/c/1XAsf2hIRJHJmx
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
This document discusses estimates and forward-looking statements regarding a pharmaceutical company focused on developing products for gastrointestinal disorders. It contains 3 late-stage clinical trials, including Phase III trials for hemorrhoids and anal fissures. The document outlines risks and uncertainties that could impact projections, including regulatory approval, clinical trial results, funding, and competition. It also provides details on management experience and the development plans and milestones for the company's lead product candidates.
Sanofi reported strong Q1 2023 results, with sales growth of 5.5% overall. The Specialty Care unit grew 18.3% driven by Dupixent sales increasing 39.7%. Dupixent continues to see strong demand globally. Vaccines sales grew 15.2% from COVID contracts and travel/booster vaccine recovery. R&D advancements included positive Dupixent COPD data and upcoming events for fitusiran and tolebrutinib. Financial guidance and outlook will be provided later in the year.
Sanofi reported strong Q1 2023 results, with specialty care sales up 18.3% driven by Dupixent growth of 39.7%. Vaccines sales also grew 15.2% from COVID contracts and travel vaccine recovery. R&D updates included positive Dupixent COPD data and promising early immunology assets. The document provided financial and business performance summaries for Q1 2023 and outlook.
Annovis Bio (NYSE American: ANVS) is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down Syndrome (AD-DS). Annovis is believed to be the only company developing a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and improves the information highway of the nerve cell, known as axonal transport. When this information flow is impaired, the nerve cell gets sick and dies. The company expects its treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain function in PD. Annovis has an ongoing Phase 2a study in AD patients and plans to commence a second Phase 2a study in PD patients. Learn more at ANVSinfo.com.
This document discusses a pharmaceutical company focused on developing drugs for gastrointestinal disorders. It provides estimates and forward-looking statements about 3 late-stage clinical trials investigating treatments for hemorrhoids, anal fissures, and fecal incontinence. It notes risks and uncertainties that could influence projections, and that actual results may differ from estimates. Key company leadership and development team members are also summarized.
FORXIGA is the first SGLT2 inhibitor approved by BPOM for the treatment of symptomatic chronic stable heart failure with reduced ejection fraction, as an adjunct to standard of care therapy. A study found that FORXIGA reduced the risk of the primary composite outcome in patients with heart failure with reduced ejection fraction. Additionally, treatment with FORXIGA resulted in a clinically meaningful improvement in heart failure symptoms and quality of life as measured by the Kansas City Cardiomyopathy Questionnaire.
RespireRx Pharmaceuticals Inc. Executives Participating in the 2nd Annual Int...RespireRX
RespireRx Pharmaceuticals is a clinical stage pharmaceutical company focused on developing drugs to treat diseases of neuronal dysfunction. Executives from RespireRx will participate in the 2nd Annual International Cannabinoid Derived Pharmaceuticals Summit to discuss cannabinoid formulations and the investor perspective on cannabinoid drugs. RespireRx is developing dronabinol for obstructive sleep apnea and researching ampakines for attention deficit hyperactivity disorder and other neurological conditions.
1) The document discusses Ophthotech's development of new therapies for age-related macular degeneration (AMD), including their lead drug Fovista.
2) Fovista is currently in Phase 3 clinical trials in combination with anti-VEGF drugs to treat wet AMD, with initial data expected in 4Q 2016.
3) Previous Phase 2b results showed Fovista in combination with Lucentis was statistically superior to Lucentis alone and had a favorable safety profile.
A New Perspective On Survival Outcomes In Multiple SclerosisJustin Knight
This document discusses new findings on survival outcomes in multiple sclerosis (MS) from international registries and databases. It summarizes that MS patients have a mean decrease in survival time of 6 to 12 years compared to the general population. A 21-year follow-up study of interferon beta-1b treatment showed that early treatment may positively impact long-term mortality rates in MS patients compared to delayed treatment. The findings suggest that early and continued disease-modifying treatment may improve long-term survival outcomes for individuals with MS.
- Olivier Brandicourt, CEO of Sanofi, presented at the JP Morgan Healthcare Conference in San Francisco on January 9, 2018.
- The presentation outlined Sanofi's progress on its 2020 strategic roadmap and focused on building leadership in specialty care and strengthening its diabetes portfolio.
- Sanofi is sustaining innovation in R&D to support long-term growth through advancing its pipeline of over 70 projects, with 9 potential regulatory submissions expected in the next 18 months.
Similar to Reviva Pharmaceuticals Holdings Presentation September 2021 (20)
Based in Ann Arbor, Michigan, Zomedica is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. With modest cash burn and a strong balance sheet, including $142.4 million cash and cash equivalents as of June 30, 2023, Zomedica is well-positioned to fund both organic growth and acquisitions.
Docola has developed a healthcare communication platform that utilizes asynchronous telehealth to deliver patient education and support. Their proprietary platform currently has over 55,000 patient users and over 1,100 clinician users. Docola seeks to raise up to $500,000 through a convertible note to fund working capital, research and development, and costs associated with an upcoming IPO.
- INNO Holdings is presenting an IPO investor presentation for an initial public offering on the NASDAQ Capital Market.
- The company manufactures prefabricated steel building components and systems using proprietary technology to reduce construction costs and environmental impact.
- INNO Holdings has four initial product lines - metal studs, prefabricated housing units, modular apartment buildings, and a mobile factory system. It aims to disrupt the construction industry through standardized, sustainable construction methods.
Everything Blockchain builds platforms of trust for the modern enterprise and is on a mission to ensure every organization has access to the tools and platforms that enable them to manage, store, and protect data without the cost and complexity that holds them back today. The Company’s patented advances in engineering deliver the essential elements needed for real-world business use: speed, security, and efficiency. Everything Blockchain’s current business lines include: EB Advise, Build DB and EB Control.
ASP Isotope is an isotope enrichment company utilizing technology developed in South Africa over the past 20 years to enrich isotopes of elements or molecules with low atomic masses. Many of these elements are unsuitable for enrichment using traditional methods such as centrifuges. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries.
MDNA Life Sciences is a pioneer in the science of mitochondrial DNA. It’s our mission to create an extensive portfolio of proprietary tests that dramatically improve diagnosis, treatment, prognosis and monitoring. Putting an end to the unnecessary surgical procedures, pain and uncertainty that affect patients across the world.
Digital Ally, Inc. is a diversified holding company with operations in video solution technology, human and animal health protection products, healthcare revenue cycle management, ticket brokering and marketing, and event production. The Company pursues an acquisition strategy that targets organizations with positive earnings, strong growth potential, innovation, and operational synergies. To maximize long-term shareholder value, Digital Ally intends to spin-off its ticketing and entertainment business lines into a separate public company in 2023. The spin-off will create two optimized, tech-driven public companies with strong growth opportunities and operating metrics.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
Aditxt is a biotech company developing immune monitoring and immune modulation platforms. Its AditxtScore platform can provide comprehensive immune profiles to monitor responses to pathogens, vaccines, drugs and transplants. Its Adimune platform aims to modulate the immune system to treat conditions like psoriasis, type 1 diabetes, and increase skin allograft survival. The company is working to develop, operate and commercialize these platforms. It currently generates revenue from immune monitoring tests and expects revenue from licensing deals for immune modulation programs as they advance in clinical trials towards commercialization.
1847 Holdings LLC, a publicly traded diversified acquisition holding company, was founded by Ellery W. Roberts, a former partner of Parallel Investment Partners, Saunders Karp & Megrue and Principal of Lazard Freres Strategic Realty Investors. EFSH's investment thesis is that capital market inefficiencies have left the founders and/or stakeholders of many small business enterprises and lower-middle market businesses with limited exit options, despite the intrinsic value of their business. Given this dynamic, EFSH can consistently acquire "solid" businesses for reasonable multiples of cash flow and then deploy resources to strengthen the infrastructure and systems to improve operations. These improvements may lead to a sale or IPO of an operating subsidiary at considerably higher valuations than the purchase price (as successfully demonstrated with the mid-2020 IPO of 1847 Goedeker on the NYSE American) and/or alternatively, an operating subsidiary may be held in perpetuity and contribute to EFSH's ability to pay regular and special dividends to shareholders.
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The Company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and is on track to launch this new product line in Q4 2023. The Company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US.
SPI Energy is a global renewable energy company and provider of solar storage and electric vehicle (EV) solutions that was founded in 2006 in Roseville, California and is headquartered in McClellan Park, California. The Company has three core divisions: SolarJuice which has solar wholesale distribution, as well as residential solar and roofing installation and solar module manufacturing (Solar4America & SEM Wafertech), SPI Solar and Orange Power which operates a commercial & utility solar division, and the EdisonFuture/Phoenix Motor EV division. SolarJuice is the leader in renewable energy system solutions for residential and small commercial markets and has extensive operations in the Asia Pacific and North America markets. The SPI Solar commercial & utility solar division provides a full spectrum of EPC services to third party project developers, and develops, owns and operates solar projects that sell electricity to the grid in multiple regions, including the U.S., U.K., and Europe. Phoenix Motor is a leader in medium-duty commercial electric vehicles, and is developing EV charger solutions, electric pickup trucks, electric forklifts, and other EV products. SPI maintains global operations in North America, Australia, Asia and Europe and is also targeting strategic investment opportunities in fast growing green energy industries such as battery storage, charging stations, and other EVs which leverage the Company's expertise and substantial solar cash flow.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
BioVie is a clinical-stage company developing what it believes will be transformative therapies to overcome unmet medical needs in neurodegeneration and liver disease. The Company is developing NE3107 for Alzheimer’s (AD) and Parkinson’s (PD) and BIV201 for refractory ascites and HRS-AKI.
Lantern Pharma is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 25 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies including eleven cancer indications and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0-2.0 million per program.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
Splash Beverage Group, an innovator in the beverage industry, owns a growing portfolio of alcoholic and non-alcoholic beverage brands including Copa di Vino wines by the glass, SALT naturally flavored tequilas, Pulpoloco Sangria, and TapouT performance hydration and recovery drinks and TapouT Cognitive Energy Drink. Splash’s strategy is to rapidly develop early-stage brands already in its portfolio as well as acquire and then accelerate brands that have high visibility or are innovators in their categories. Led by a management team that has built and managed some of the top brands in the beverage industry and led sales from product launch into the billions, Splash is rapidly expanding its brand portfolio and global distribution.
BullFrog AI is a technology enabled drug development company using machine learning to usher in a new era of precision medicine. Through its collaborations with leading research institutions, including Johns Hopkins University and J. Craig Venter Institute, BullFrog AI is at the forefront of AI-driven drug development. Using its proprietary bfLEAP™ artificial intelligence platform, BullFrog AI aims to enable the successful development of pharmaceuticals and biologics by predicting which patients will respond to therapies in development. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics, and impacting the lives of countless patients that may have otherwise not received the therapies they need.
2024 Media Preferences of Older Adults: Consumer Survey and Marketing Implica...Media Logic
When it comes to creating marketing strategies that target older adults, it is crucial to have insight into their media habits and preferences. Understanding how older adults consume and use media is key to creating acquisition and retention strategies. We recently conducted our seventh annual survey to gain insight into the media preferences of older adults in 2024. Here are the survey responses and marketing implications that stood out to us.
Cancer treatment has advanced significantly over the years, offering patients various options tailored to their specific type of cancer and stage of disease. Understanding the different types of cancer treatments can help patients make informed decisions about their care. In this ppt, we have listed most common forms of cancer treatment available today.
Solution manual for managerial accounting 18th edition by ray garrison eric n...rightmanforbloodline
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Solution manual for managerial accounting 18th edition by ray garrison eric noreen and peter brewer_compressed
Health Tech Market Intelligence Prelim Questions -Gokul Rangarajan
The Ultimate Guide to Setting up Market Research in Health Tech part -1
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
This lays foundation of scoping research project what are the
Before embarking on a research project, especially one aimed at scoping and defining parameters like the one described for health tech IT, several crucial considerations should be addressed. Here’s a comprehensive guide covering key aspects to ensure a well-structured and successful research initiative:
1. Define Research Objectives and Scope
Clear Objectives: Define specific goals such as understanding market needs, identifying new opportunities, assessing risks, or refining pricing strategies.
Scope Definition: Clearly outline the boundaries of the research in terms of geographical focus, target demographics (e.g., age, socio-economic status), and industry sectors (e.g., healthcare IT).
3. Review Existing Literature and Resources
Literature Review: Conduct a thorough review of existing research, market reports, and relevant literature to build foundational knowledge.
Gap Analysis: Identify gaps in existing knowledge or areas where further exploration is needed.
4. Select Research Methodology and Tools
Methodological Approach: Choose appropriate research methods such as surveys, interviews, focus groups, or data analytics.
Tools and Resources: Select tools like Google Forms for surveys, analytics platforms (e.g., SimilarWeb, Statista), and expert consultations.
5. Ethical Considerations and Compliance
Ethical Approval: Ensure compliance with ethical guidelines for research involving human subjects.
Data Privacy: Implement measures to protect participant confidentiality and adhere to data protection regulations (e.g., GDPR, HIPAA).
6. Budget and Resource Allocation
Resource Planning: Allocate resources including time, budget, and personnel required for each phase of the research.
Contingency Planning: Anticipate and plan for unforeseen challenges or adjustments to the research plan.
7. Develop Research Instruments
Survey Design: Create well-structured surveys using tools like Google Forms to gather quantitative data.
Interview and Focus Group Guides: Prepare detailed scripts and discussion points for qualitative data collection.
8. Sampling Strategy
Sampling Design: Define the sampling frame, size, and method (e.g., random sampling, stratified sampling) to ensure representation of target demographics.
Participant Recruitment: Plan recruitment strategies to reach and engage the intended participant groups effectively.
9. Data Collection and Analysis Plan
Data Collection: Implement methods for data gathering, ensuring consistency and validity.
Analysis Techniques: Decide on analytical approaches (e.g., statistical
Test bank advanced health assessment and differential diagnosis essentials fo...rightmanforbloodline
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
Test bank advanced health assessment and differential diagnosis essentials for clinical practice 1st edition myrick.
The Ultimate Guide in Setting Up Market Research System in Health-TechGokul Rangarajan
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
"Market Research it too text-booky, I am in the market for a decade, I am living research book" this is what the founder I met on the event claimed, few of my colleagues rolled their eyes. Its true that one cannot over look the real life experience, but one cannot out beat structured gold mine of market research.
Many 0 to 1 startup founders often overlook market research, but this critical step can make or break a venture, especially in health tech.
But Why do they skip it?
Limited resources—time, money, and manpower—are common culprits.
"In fact, a survey by CB Insights found that 42% of startups fail due to no market need, which is like building a spaceship to Mars only to realise you forgot the fuel."
Sudharsan Srinivasan
Operational Partner Pitchworks VC Studio
Overconfidence in their product’s success leads founders to assume it will naturally find its market, especially in health tech where patient needs, entire system issues and regulatory requirements are as complex as trying to perform brain surgery with a butter knife. Additionally, the pressure to launch quickly and the belief in their own intuition further contribute to this oversight. Yet, thorough market research in health tech could be the key to transforming a startup's vision into a life-saving reality, instead of a medical mishap waiting to happen.
Example of Market Research working
Innovaccer, founded by Abhinav Shashank in 2014, focuses on improving healthcare delivery through data-driven insights and interoperability solutions. Before launching their platform, Innovaccer conducted extensive market research to understand the challenges faced by healthcare organizations and the potential for innovation in healthcare IT.
Identifying Pain Points: Innovaccer surveyed healthcare providers to understand their difficulties with data integration, care coordination, and patient engagement. They found widespread frustration with siloed systems and inefficient workflows.
Competitive Analysis: Analyzed competitors offering similar solutions in healthcare analytics and interoperability. Identified gaps in comprehensive data aggregation, real-time analytics, and actionable insights.
Regulatory Compliance: Ensured their platform complied with HIPAA and other healthcare data privacy regulations. This compliance was crucial to gaining trust from healthcare providers wary of data security issues.
Customer Validation: Conducted pilot programs with several healthcare organizations to validate the platform's effectiveness in improving care outcomes and operational efficiency. Gathered feedback to refine features and user interface.
2. 2
This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended,
including those relating to the Company's product development and clinical trial plans, clinical and regulatory timelines, trial
results, market opportunity, competitive position, possible or assumed future results of operations, business strategies,
potential growth and financing opportunities and other statements that are predictive in nature. These forward-looking
statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which
we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-
looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential,"
"predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to
future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including
the potential impact of the recent COVID19 pandemic and the potential impact of sustained social distancing efforts, on our
operations, clinical development and clinical trial plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange
Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which
speak only as of the date of this presentation. The Company undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events or otherwise.
Forward Looking Statements
3. 3
Company
Overview
Lead Asset:
RP5063
Market
Opportunity
Financials
Publicly listed in December 2020
Trading under NASDAQ symbol: RVPH
Extensive clinical pipeline with lead program phase 3 in schizophrenia estimated to commence in Q4’21
Orphan Drug Designation for the treatment of pulmonary arterial hypertension (PAH) & idiopathic
pulmonary fibrosis (IPF)
Global addressable market size for RP5063
$7.9 B for schizophrenia by 20221; $5.4 B for bipolar disorder by 20242; $15.9 B for depression by 20233;
$24.9 B for ADHD by 20254; $14.6 B for PAH by 20265; $5.9 B for IPF by 20236
Clinical-stage pharmaceutical company developing therapies for central nervous system, cardiovascular,
metabolic, and inflammatory diseases
Investment Highlights
1. Grand View Research, Inc., 2017
2. Bipolar Disorder: Market Data Forecast 2020
3. Depression: Allied Market Research 2018
4. ADHD: Grand View Research in 2019
5. PAH: Credence Research, 2018
6. IPF: iHealthcare Analyst 2018
4. 4
Experienced Leadership Team
Proven track record in Biotechnology and Pharmaceutical Development
Laxminarayan Bhat, PhD
Chief Executive Officer
Narayan Prabhu
Chief Financial Officer
Marc Cantillon, MD
Chief Medical Officer
5. 5
NCE (Program) Target Indications Development Phase
Discovery Preclinical Phase I Phase II Phase III
RP5063
(Neuropsychiatric)
Schizophrenia
Bipolar Disorder
Depression MDD
Attention Deficit Hyperactivity Disorder
(ADHD)
Parkinson’s Psychosis
Alzheimer’s (Psychosis/agitation)
RP5063
(Pulmonary)
Pulmonary Arterial Hypertension (PAH)
Idiopathic Pulmonary Fibrosis (IPF)
RP1208
Depression
Obesity
RP1208 RP5063
Extensive Clinical Development Pipeline
* Q4’21 estimated
Phase 3 trial initiation
6. 6
Dysfunctional Serotonin Signaling Causes Neuropsychiatric Disorders
and Lung Diseases PAH and IPF
The mechanistic
connection between
neuropsychiatric
disorders and interstitial
lung diseases.
Analogous dysfunctional
dopamine and serotonin
receptor signaling
processes occurring in
the brain have been
implicated in the
pathogenesis of
schizophrenia and other
neuropsychiatric
disorders, and serotonin
receptor signal process
in the pathogenesis of
lung conditions such a
pulmonary arterial
hypertension (PAH) &
idiopathic pulmonary
fibrosis (IPF), respectively.
[ OFC: Orbitofrontal cortex;
PFC: prefrontal cortex ]
Cantillon, M. et al. Schizophrenia Research 2017, 189: 126-133; Bhat et al., Eur J Pharmacol 2018, 827:159-166; Wang, Q. et al. Pharmaceuticals 2021, 14, 76.
7. 7
Addressing Significant Unmet Medical Needs
Neuropsychiatric Programs
Depression
$15.9B
by 20233
Schizophrenia
$7.9B
by 20221
Bipolar Disorder
$5.4B
by 20242
Pulmonary Programs
Idiopathic Pulmonary
Fibrosis (IPF)
$5.9B
by 20236
Pulmonary Arterial
Hypertension (PAH)
$14.6B
by 20265
ADHD
$24.9B
by 20254
1. Grand View Research, Inc., 2017
2. Bipolar Disorder: Market Data Forecast 2020
3. Depression: Allied Market Research 2018
4. ADHD: Grand View Research in 2019
5. PAH: Credence Research, 2018
6. IPF: iHealthcare Analyst 2018
9. 9
Suboptimal Efficacy2,3,4
• Negative symptoms
• Cognitive deficits
• Mood symptoms
Poor Tolerability/Side Effects3
• Neurological (EPS, akathisia)
• Metabolic (obesity, diabetes, cholesterol)
• Endocrine (sexual dysfunction)
Schizophrenia affects ~1% of the world’s population and ~3.2 million people in the US.
Yet there are currently no therapies that adequately address the complex mix of positive & negative
symptoms, mood, and cognitive impairment associated with schizophrenia.1
High Discontinuation/Non-compliance4,5
Reviva estimates discontinuation rates of 30-50% in short-term treatment
of acute patients and 42-74% in long-term treatment of stable patients
1. American Addiction Centers Resource: https://www.mentalhelp.net/schizophrenia/statistics/ (April 24, 2021)
2. Torres-Gonzalez F et al, Neuropsychiatric Disease and Treatment 2014, 10:97-110.
3. Stroup T S and Gray N, World Psychiatry 2018, 17:341-356.
No Therapies Adequately Address Symptoms of Schizophrenia
4. Bhat L et al, J Neurology and Neuromedicine 2018 , 3(5): 39-50.
5. Levin, S.Z. et al., Schizophrenia Research 2015, 164:122-126.
10. 10
RP5063: Multimodal Modulator of Serotonin and Dopamine Receptors
RP5063
5-HT
SERT
D
Nicotinic
Ach
Drug Receptor
Partial Agonist
Antagonist
RP5063
RP5063
5-HT2A/2B/7
D2/3/4
RP5063 has a broad in vitro pharmacology profile
against key dopamine (D) and serotonin (5-HT)
receptors which can stabilize the D/5-HT system
RP5063 pharmacologically differs from other antipsychotics
through its combination of potent affinity and selectivity
for target receptors implicated for schizophrenia and its
comorbid symptoms
Weak or no significant activities for off-targets (5-HT2C, 1,2,
M3) that are implicated for adverse/side effects
RP5063 modulates receptor signaling RP5063 has high affinity & selectivity
11. 11
RP5063 Phase 2 Schizophrenia Trial Design
Randomized, double-blind, placebo-controlled, multicenter (USA, EU, Asia) trial to assess the safety and
efficacy of RP5063 in subjects with acute exacerbation of schizophrenia or schizoaffective disorder
28 42 ± 2
Double-blind treatment
Day -6 0 1
Screening Follow-up
Re-stabilization
35 ± 2
Women
RP5063, 15mg
RP5063, 30mg
RP5063, 50mg
Placebo
Aripiprazole,
15mg*
N = 60
N = 60
N = 60
N = 40
N = 20
Randomized
3:3:3:2:1
Schizophrenia
Patients
N = 240 Men
The aripiprazole arm was included solely to show assay sensitivity and was not powered to show efficacy.
Primary Endpoint:
Reduction in total PANSS at
the end of treatment in
RP5063 arm from baseline
versus placebo
Safety:
Clinical, labs, body weight,
prolactin, lipids, fasting
glucose, EKG
Pharmacokinetics:
Population pharmacokinetics
Study Overview
12. 12
Brilaroxazine (RP5063) Phase 2 Efficacy Data in Schizophrenia with
Sustained Decrease in PANSS Total Score
60
70
80
90
100
RP5063 - 15mg
(P = <0.001)
RP5063 - 30mg
(P = <0.001)
RP5063 - 50mg
(P = <0.001)
Aripiprazole - 15mg
(P = <0.013)
Placebo
(P = <0.001)
Day 1 Day 4 Day 8 Day 15 Day 22 Day 28
PANSS
Total
Score
- 20 points
- 15 points
- 19 points
- 11 points
- 9 points
*Statistical significance within the group
* * * * *
* In RP5063 group 30 mg group 6 patients dropped out within a week for non-medical reasons; population PK and PK/PD results support the data quality and uniformity. It
is not uncommon to see patient dropping out due to non-medical reasons in schizophrenia trials, Winlow et al, Clinical Impact Review (Core Med Pub) 2006.
Reduction in
PANNS Total Score
N = 234 / 4-week
13. 13
RP5063: Statistically Significant Treatment Difference from Placebo
-30
-25
-20
-15
-10
-5
0
1 2 3 4 5 6 7
Least
Squares
Mean
±SE
MMRM Analysis; Full Dataset
PANSS Total, Change from Baseline
Placebo
15 mg
30 mg
50 mg
EOT
Baseline Day 4 Day 8 Day 15 Day 22 Day 28
* *
*
*
*
* *
* p<0.05
Cantillon, M. et al. Schizophrenia Research 2017, 189: 126-133
Efficacy Data
for Schizophrenia
14. 14
RP5063: Mitigated Positive and Negative Symptoms, Improved
Prosocial Functioning
Cantillon, M. et al. Schizophrenia Research 2017, 189: 126-133
-10
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1 2 3 4 5 6 7
Least
Squares
Mean
±SE
MMRM Analysis; Full Dataset
PANSS Positive, Change from Baseline
Placebo
15 mg
30 mg
50 mg
EOT
Baseline Day 4 Day 8 Day 15 Day 22 Day 28
*
*
-6
-5
-4
-3
-2
-1
0
1
1 2 3 4 5 6 7
Least
Squares
Mean
±SE
MMRM Analysis; Full Dataset
PANSS Negative, Change from Baseline
Placebo
15 mg
30 mg
50 mg
EOT
Baseline Day 4 Day 8 Day 15 Day 22 Day 28
*
*
*
*
*
*
*
*
*
* *
*
*
-9
-8
-7
-6
-5
-4
-3
-2
-1
0
1 2 3 4 5 6
Least
Squares
Mean
±SE
MMRM Analysis; Full Dataset
PANSS Prosocial, Change from Baseline
Placebo
15 mg
30 mg
50 mg
Baseline Day 4 Day 8 Day 15 Day 22 Day 28
*
** *
*
**
*
*
***
* p<0.05, ** p<0.01, *** p<0.001
Decrease in Positive
Symptoms (PANSS)
Decrease in Negative
Symptoms (PANSS)
Improvement in Social
Functioning (PANSS)
15. 15
Clean Side Effect Profile: Neuroleptic, Endocrine and Metabolic Side
Effects of RP5063 Comparable to Placebo
Cantillon, M. et al. Schizophrenia Research 2017, 189: 126-133
Ari: Aripiprazole; RP: Brilaroxazine (RP5063)
RP: 15mg projected, widely used dose
Extrapyramidal Side Effect (%) Change in Prolactin (mIU/L)
Akathisia (%) Change in Thyroid-T4 (pmol/L)
Body Weight Increase (%) Diabetes/Blood Sugar (mmol/L) Lipids/Triglycerides (mmol/L)
Cholesterol (mmol/L)
CNS / Neuroleptic Side Effects Endocrine Side Effects
Metabolic Side Effects
16. 16
Current Positioning of Brilaroxazine (RP5063) vs Major Antipsychotics
Reviva Sponsored Research from Zacks SC Research, April 2021; Lancet 2019, 394:939-951.
Meta-Analysis of RP5063
Phase 2 Efficacy Data and
Side Effects with the
Clinical Data of Major
Antipsychotics
Brilaroxazine (RP5063)
17. 17
RP5063: Ready for a Phase 3 Trial in Schizophrenia
Phase 1 Phase 2 Phase 3
Key
Findings
Next
Steps
Current Stage
Study
Design
• Patients diagnosed with
stable schizophrenia (Phase
1B) and healthy subjects
(Phase 1A)
• Patients diagnosed with
acute schizophrenia
• Phase 3 studies planned for
acute schizophrenia
• Well tolerated, no dose-
limiting safety signals
• Decrease in positive
symptoms & improvement in
cognition after 10 days
(Phase 1B)
• Met primary endpoint of
reduction in total PANSS at
the end of treatment
• Well-tolerated, favorable
safety profile
• Supported initiation of Phase
2 study to further evaluate
efficacy and safety
• Successful End of Phase 2
meeting with US FDA
• FDA guidance for potential
‘Superior Safety’ label claim
• FDA has already reviewed
Phase 3 protocol, CMC, and
long-term toxicology package
• Phase 3 studies for acute
schizophrenia expected to
commence in 4Q’ 21,
following the financing closed
in June 2021
20. 20
RP5063: Preclinical Data for PAH in Translational Models
Bhat and Salvail, J Rare Dis Res Treat 2017, 2(5): 5-12. Bhat, et al. European J Pharmacology 2017, 810:83-91 and 92-99.
Bhat, et al. European J Pharmacology 2018, 827: 159-166.
• RP5063 demonstrated encouraging results for PAH in
both MCT and Sugen-Hypoxia rodent models
• Mitigated PAH
• Decreased respiratory resistance & restored blood
oxygen saturation
• Decreased vascular remodeling & fibrosis in the small
vessels
• Mitigated inflammation & reduced small vessel
thickness
• Significantly reduced inflammatory cytokines TNF,
IL-β, IL-6, and chemokine LTB4
RP5063 both alone & co-administered with
standard of care for PAH
Treatment effects on PAH
21. 21
RP5063: Preclinical Data for IPF in Translational Model
Bhat et al., (unpublished data)
• RP5063 demonstrated encouraging results for IPF in
bleomycin-induced IPF rodent model
• Mitigated lung fibrosis and collagen deposits
• Decreased respiratory resistance & improved blood
oxygen saturation
• Restored body weight and cardiac output
• Reduced the IPF biomarkers BALF cell counts,
hydroxyproline, and blood lactate levels
• Decreased cytokines RANTES, IFN, MCP1, IL-6, and
IL-17
• Improved survival rates
RP5063 both alone and co-administered
with standard of care for IPF
RP5063 mitigates lung fibrosis/collagen
(Decrease in Hydroxyproline)
22. 22
RP5063: Improves Survival Rate in IPF Bleomycin (BLM) Induced IPF
Rodent Model
Bhat et al., (unpublished data)
Mitigates Respiratory Resistance Improves Survival Rate
23. 23
RP5063: Ready for Phase 2 Trials in PAH and IPF
Bhat et al., Eur J Pharmacol 2018, 827:159-166
• Preclinical evidence supports the use of
RP5063 in PAH and IPF
• Generally well-tolerated in clinical studies for
schizophrenia in >250 patients
• Completed long-term regulatory toxicology
studies
• Manufactured API and drug products (clinical
trial materials)
• Oral once daily dosing, potential to develop
once daily inhaler for enhanced effect and
convenience
RP5063 Phase 2 trials in PAH and IPF
✓ FDA reviewed preclinical pharmacology,
toxicology, CMC, and clinical Phase 1 safety data
for initiating a Phase 2 study
✓ FDA reviewed and provided guidance on Phase
2/3 clinical development plan and a potential
“Disease Modifying Agent” label claim
✓ FDA granted Orphan Drug Designation to
RP5063 for the treatment of PAH & IPF
RP5063 achieved key regulatory milestones
24. 24
Company
Overview
Lead Asset:
RP5063
Market
Opportunity
Financials
Publicly listed in December 2020
Trading under NASDAQ symbol: RVPH
Extensive clinical pipeline with lead program phase 3 in schizophrenia estimated to commence in Q4’21
Orphan Drug Designation for the treatment of pulmonary arterial hypertension (PAH) & idiopathic
pulmonary fibrosis (IPF)
Global addressable market size for RP5063
$7.9 B for schizophrenia by 20221; $5.4 B for bipolar disorder by 20242; $15.9 B for depression by 20233;
$24.9 B for ADHD by 20254; $14.6 B for PAH by 20265; $5.9 B for IPF by 20236
Clinical-stage pharmaceutical company developing therapies for central nervous system, cardiovascular,
metabolic, and inflammatory diseases
Investment Highlights
1. Grand View Research, Inc., 2017
2. Bipolar Disorder: Market Data Forecast 2020
3. Depression: Allied Market Research 2018
4. ADHD: Grand View Research in 2019
5. PAH: Credence Research, 2018
6. IPF: iHealthcare Analyst 2018
25. 25
25
Global Operations
U.S. Headquarters
19925 Stevens Creek Blvd., Suite 100
Cupertino, CA 95014
United States
Investor Relations Contact
LifeSci Advisors, LLC
IR@Revivapharma.com
info@Revivapharma.com
General Inquiries